WindMIL Therapeutics and University of★←↕ California, Irvine Announce Collaborat∞>ion to Collect Bone Marrow from Patien​γts with GliomasWEDNESDAY, OCTOBER 16λ'☆λ, 2019WindMIL Therapeutics and t♦§♠he University of California, Irvine (UCI) to→₩©​day announced that the first patient∏×s have been identified"σ in an investigator-sponsored study for the ♣γcollection of bone marrow from↕¶≠β patients with gliomas. Th₽ε☆e study will evaluate generating marrow infiltrat→‍♣ing lymphocytes (MILs™) for these patients &↔÷εthrough WindMIL’s prop↕‍÷↕rietary cellular activation and expansion ®λprocess. The study is being conduc↑‌​ted at UCI.“Patients suffering with gli★•oblastoma are in great need of new,ε$←σ promising treatments that might ©<☆♦advance the current standard∑δ of care,” said Daniela A. Bota, MD, PhD  ≥, director of the UCI Health Comprehensive Br↓§ain Tumor Program, senior associate♦♦α§ dean for clinical research, UCI Sch≈♣ool of Medicine and clinical director, UCI Sue ↕'& Bill Gross Stem Cell Resear✘↓ch Center. “The University λ of California, Irvine is excit∞∑ed to play a key role in↔↑ research that may lead to a clinical t®¶©σrial that enlists the immune syst₹✘₹✔em in novel ways to fight this terrible dis↓×ease.”Gliomas are thγ ↓e most common of the malig÷¥€↔nant brain tumors. Glioblastoma, the most commo§♥₽n glioma, has a five-year surviva‍  ≤l of less than 5 percent. Additional treatment op∞"​tions are urgently needed for ☆₩&₽these patients. Adoptiδ₽±ve immunotherapy is a possible approach for gliomλ↓πas and the use of MILs, a cell therapy tha≥₹t is naturally tumor-specif♥±♠>ic, is one such treatment option≠₽.The bone marrow is a u∏♠∑nique niche in the immune system to whi☆↓≤ch antigen-experienced memory  &&T cells traffic and are then maintained. Wind±∞α MIL has developed a proprietary p↕<rocess to select, activate and ex≈÷♣♦pand these memory T cells into MILs. Because €$memory T cells in bone marrow occur as a re≤ ♦sult of the immune system’s rec≈<>↓ognition of tumor antigens, MILs are spe₽' ♦cifically suited for adoptive cellular im•↑↑★munotherapy and are able to directly eradicate σ♠or facilitate eradication of each ≤≈≤✘patient’s unique cancer. WindMIL is curr÷$ently studying MILs in mul€₩♣tiple myeloma, non-small cell lung cancer and squ£δ✔amous cell carcinoma oδ&§f the head and neck, and pla↔™ns to expand into other solid tumo©¶×rs.“WindMIL is looking forward≈≥™λ to working with the Univers→★ity of California, Irvine on this exciting ×εproject and is optimistic that MILs may ​∞₹offer the potential to help patients with these '♠≤£hard-to-treat diseases,” s<®♣βaid Monil Shah, PharmD,✔>§ MBA, Chief Development Officer at ♣ WindMIL.information source:pharεφ ♦ma focus AsiaThe original link:https://www.ph♦≠ armafocusasia.com/new ∏‍✔s/windmil-therapeutics-and-university-of-californ★>ia-irvine-announce-collabor↓ ation-to-collect-bone-marrow-from-patie∑γ≥¶nts-with-gliomas2019 Asi₽£a-pacific pharma IP Leader Summit: http://en.zen©‍seegroup.com/p/510934/will be h₹<→eld in Beijing  on No₽•‍εvember 14-15, and will attra♠¥★ct more than 500 industry expe™↓∑ rts from domestic and foreig÷$©n pharmaceutical companies, biotechnologyφ↑ companies, governments, associations, law firmsαπ≥↔, intellectual property ag☆≤ ents and other companies to attend.O♣ fficial registration and consultation ch♥≤annels:Contact：AnnPh ×one: 021-65650305Email：Marketing@zenseegr©γoup.comhttp://en.zenseegroup.com/p/5↑♠10934/